In states that covered obesity-labeled GLP-1 RAs, total GLP-1 RA use rose less than obesity-labeled use alone, suggesting possible substitution.
|Articles|June 9, 2021
Supplements and Featured Publications
- Moderate to Severe Psoriasis: Considerations for Patient Management Amid a Changing Treatment Spectrum
- Volume 27
- Issue 10
Participating Faculty for Moderate to Severe Psoriasis: Considerations for Patient Management Amid a Changing Treatment Spectrum
Author(s)Jerry Bagel, MD, MS
Advertisement
FACULTY
Jerry Bagel, MD, MS
Director
Psoriasis Treatment Center of New Jersey
East Windsor, New Jersey
Clinical Professor
Icahn School of Medicine at Mount Sinai
New York, New York
FACULTY DISCLOSURES
Jerry Bagel, MD, MS, has disclosed the following relevant commercial financial relationships or affiliations in the past 12 months:
BOARD MEMBERSHIP
The National Psoriasis Foundation, Board of Directors
CONSULTANCIES OR PAID ADVISORY BOARDS
AbbVie, Janssen Pharmaceuticals, Arcutis Biotherapeutics
GRANTS RECEIVED
AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Novartis,
Sun Pharma, UCB
LECTURE FEES FOR SPEAKING AT THE INVITATION OF A COMMERCIAL SPONSOR
AbbVie, Eli Lilly and Company, Janssen Pharmaceuticals
Articles in this issue
Advertisement
Related to this article
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.
SURPASS-CVOT data show fewer deaths or HF events with tirzepatide vs dulaglutide in patients with HF, driven largely by mortality.
Subcutaneous mosunetuzumab plus polatuzumab vedotin boosts responses in relapsed large B-cell lymphoma, helping community oncology care.
Using baseline samples from 177 patients in the VISION/HO141 trial, researchers built a functional prognostic model for CLL that outperformed the CLL-IPI.
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
FDA Approves First Treatment for BCG-Unresponsive Bladder Cancer
3
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
4
Dyshidrotic Eczema Less Tied to Occupation Than Other Hand Eczema
5